<DOC>
	<DOCNO>NCT02991807</DOCNO>
	<brief_summary>Phosphatase TENsin homolog ( PTEN ) gene germline mutation associate spectrum clinical manifestation characterize neurocognitive deficit , intellectual disability , autism symptomatology , skin lesion , macrocephaly , hamartomatous overgrowth tissue , increase risk cancer . Investigators conduct research evaluate potential safety efficacy RAD001 ( everolimus ) patient population , potential neurocognitive benefit treatment RAD001 placebo six month period . The investigator hope trial lead well understand PTEN new form treatment may benefit child adult PTEN future .</brief_summary>
	<brief_title>RAD001 Neurocognition PTEN Hamartoma Tumor Syndrome ( PTEN )</brief_title>
	<detailed_description>This signal seek Phase I/II 6-month , randomize , double-blind placebo-controlled trial RAD001 child adolescent , age 6 21 year PTEN mutation , safety neurocognition primary endpoint . Prior enrol study undergoing series screen test confirm eligibility , participant legal guardian need sign inform consent . If determine eligible treatment phase trial , participant randomly assign take either study drug placebo ( pill medicine ) . The study involve nine visit , six occur study site , three conduct phone . These visit take place six month period . Study visit vary length . Baseline , three month six month visit may last 8 hour , visit le 2 hour . The study visit include blood draw , laboratory test neuropsychological assessment . There fee participate study . The study drug provide charge study . After 6 month treatment phase , individual randomly assign take placebo offer inclusion 6 month open label phase study drug provide charge assessment continue initial 6 month period . After study data analyze , family inform overall result . Treatment study may may improve child 's learning skill ( neurocognition ) . Future patient may benefit learned . Specific Aims /Objectives Primary objective -To evaluate safety everolimus ( RAD001 ) compare placebo patient PTEN mutation focus NCI CTCAE Grade 3 4 adverse event , serious adverse event , Grade 3 4 laboratory toxicity . Secondary objective -To evaluate efficacy everolimus ( RAD001 ) neurocognition behavior child adolescence PTEN mutation compare placebo measure standardize , direct indirect neurocognitive tool behavioral measure .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hamartoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hamartoma Syndrome , Multiple</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Male female outpatient 6 21 year age ; 2 . Pathogenic PTEN mutation confirm clinical genetic testing ; 3 . IQ≥50 ( either verbal nonverbal ) ( IQ necessary able complete require neurocognitive developmental assessment ) 4 . Performance ageadjusted population mean least one standardized measure CPT ( mean reaction time ) Working memory ( SB5 ) Purdue Pegboard fine motor assessment ( hand ) ; 5 . Adequate bone marrow function show : platelet ≥ 80,000/mm3 , absolute neutrophil count ≥ 1,000/mm3 hemoglobin ≥ 9 g/dL 6 . Adequate liver function show : Total serum bilirubin &lt; 1.5 × upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) level &lt; 2.5 x ULN ; 7 . Adequate renal function : serum creatinine &lt; 1.5 x ULN , 8. International Normalized Ratio ( INR ) ≤2 ( Anticoagulation allow target INR ≤ 1.5 stable dose warfarin stable dose low molecular weight ( LMW ) heparin &gt; 2 week time randomization . ) 9 . Signed informed consent obtain prior screening procedure ; 10 . Individuals psychotropic antiepileptic medication maintain stable dose least 2 month prior enrollment ; 11 . If female child bear potential , documentation negative pregnancy test prior enrollment . Sexually active premenopausal female patient ( female partner male patient ) must use adequate contraceptive measure , exclude estrogen contain contraceptive , study . Abstinence consider adequate contraceptive measure . 12 . Medically stable active medical problem unstable seizure cardiovascular disease evidence history ; 13 . No anticipated change frequency intensity exist intervention behavioral developmental treatment , home service , speech therapy ; 14 . No planned change school placement ; 15 . For individual 18 otherwise incapable , must available caregiver reliably bring subject clinic visit provide trustworthy data 16 . English primary language 1 . Patients currently receive anticancer therapy receive anticancer therapy within 4 week start Everolimus ( include chemotherapy , radiation therapy , antibody base therapy , etc . ) ; 2 . Known intolerance hypersensitivity Everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) ; 3 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral Everolimus ; 4 . Uncontrolled diabetes mellitus define Glycated hemoglobin ( HbA1c ) &gt; 8 % despite adequate therapy . 5 . Patient uncontrolled hyperlipidemia : fasting serum cholesterol &gt; 300 mg/dL OR &gt; 7.75 mmol/L AND fast triglyceride &gt; 2.5 x ULN . 6 . Patients severe and/or uncontrolled medical condition active ( acute chronic ) uncontrolled severe infection active chronic hepatitis ( i.e . quantifiable Hepatitis B Virus ( HBVDNA ) and/or positive hepatitis B virus surface antigen ( HbsAg ) , quantifiable hepatitis C virus ( HCVRNA ) , know severely impaired lung function ( spirometry Diffusing capacity lung carbon monoxide ( DLCO ) 50 % less normal O2 saturation 88 % less rest room air ) , Active , bleed diathesis ; 7 . Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow ; 8 . Known history HIV seropositivity ; 9 . Patients receive live attenuate vaccine within 1 week start Everolimus study . Patient also avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , bacille Calmette Guerin ( BCG ) , yellow fever , varicella TY21a typhoid vaccine ; 10 . Patients history another primary malignancy , exception : nonmelanoma skin cancer , carcinoma situ cervix , uterus , breast patient disease free ≥3 year ; 11 . Planned change concomitant medication ; 12 . Prior concomitant therapy know possible anti mammilian target rapamycin ( mTOR ) activity , include rapamycin ( sirolimus ) ; 13 . Concomitant therapy strong inhibitor ( e.g. , cyclosporine ketoconazole ) inducer CYP3A ; 14 . Active infection time enrollment ; 15 . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study ; 16 . Patients currently part participate clinical investigation investigational drug within 1 month prior dose ; 17 . Pregnant nursing ( lactate ) woman ; 18 . Male patient whose sexual partner ( ) woman child bear potential willing use adequate contraception , study 8 week end treatment 19 . Major surgery , radiation therapy stereotactic radiosurgery within previous 4 week time enrollment 20 . Neurosurgery within prior 6 month time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PTEN</keyword>
	<keyword>PTEN Gene Mutation</keyword>
	<keyword>PTEN Hamartoma Tumor Syndrome</keyword>
	<keyword>Autism</keyword>
	<keyword>Intellectual Disability</keyword>
	<keyword>Neurocognition</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Everolimus</keyword>
	<keyword>RAD001</keyword>
</DOC>